Albert Saiz

List of Publications by Year
in descending order

194 papers	19,722 citations	13865 67 h-index	11607 135 g-index
200 all docs	200 docs citations	200 times ranked	13021 citing authors

#	Article	IF	Citations
1	The role of specialist nurses in detecting spasticity and related symptoms in multiple sclerosis. Journal of Clinical Nursing, 2023, 32, 3496-3503.	3.0	1
2	Impact of COVID-19 in Immunosuppressed Children With Neuroimmunologic Disorders. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	8
3	Aquaporin-4-Positive Triple-Negative Breast Cancer Presenting with Paraneoplastic Neuromyelitis Optica Spectrum Disorder. Biomedicine Hub, 2022, 7, 11-16.	1.2	2
4	Identification of the genetic mechanism that associates L3MBTL3 to multiple sclerosis. Human Molecular Genetics, 2022, 31, 2155-2163.	2.9	4
5	Neurofilament Light Chain Levels in Anti-NMDAR Encephalitis and Primary Psychiatric Psychosis. Neurology, 2022, 98, .	1.1	25
6	Clinically reversible ustekinumab-induced encephalopathy: case report and review of the literature. Therapeutic Advances in Neurological Disorders, 2022, 15, 175628642210796.	3.5	4
7	Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology. Frontiers in Immunology, 2022, 13, 842354.	4.8	1
8	Association of Maintenance Intravenous Immunoglobulin With Prevention of Relapse in Adult Myelin Oligodendrocyte Glycoprotein Antibodyâ€“Associated Disease. JAMA Neurology, 2022, 79, 518.	9.0	39
9	Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology. Multiple Sclerosis and Related Disorders, 2022, 63, 103805.	2.0	2
10	Applying multilayer analysis to morphological, structural, and functional brain networks to identify relevant dysfunction patterns. Network Neuroscience, 2022, 6, 916-933.	2.6	10
11	Worldwide Incidence and Prevalence of Neuromyelitis Optica. Neurology, 2021, 96, 59-77.	1.1	101
12	Seizure-related 6 homolog like 2 autoimmunity. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	36
13	Late Onset Macular Oedema in a Patient with Multiple Sclerosis Treated with Fingolimod. Neuro-Ophthalmology, 2021, 45, 61-64.	1.0	5
14	Oligoclonal IgM bands in the cerebrospinal fluid of patients with relapsing MS to inform long-term MS disability. Multiple Sclerosis Journal, 2021, 27, 1706-1716.	3.0	8
15	Incidence and Impact of COVID-19 in MS. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	29
16	Cortical fractal dimension predicts disability worsening in Multiple Sclerosis patients. NeuroImage: Clinical, 2021, 30, 102653.	2.7	21
17	Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis. Neurology, 2021, 96, .	1.1	41
18	Clinical, Neuroimmunologic, and CSF Investigations in First Episode Psychosis. Neurology, 2021, 97, e61-e75.	1.1	54

#	Article	IF	Citations
19	Encephalitis with Autoantibodies against the Glutamate Kainate Receptors <scp>GluK2</scp>. Annals of Neurology, 2021, 90, 101-117.	5.3	26
20	Thymoma and Autoimmune Encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	28
21	004â€…Pregnancy-related relapse in natalizumab, fingolimod and dimethyl fumarate-treated women with multiple sclerosis. , 2021, , .		0
22	Regional grey matter microstructural changes and volume loss according to disease duration in multiple sclerosis patients. Scientific Reports, 2021, 11, 16805.	3.3	17
23	CSF Chitinase 3â€“Like 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	15
24	Absence of GluD2 Antibodies in Patients With Opsoclonus-Myoclonus Syndrome. Neurology, 2021, 96, e1082-e1087.	1.1	9
25	Dynamics and Predictors of Cognitive Impairment along the Disease Course in Multiple Sclerosis. Journal of Personalized Medicine, 2021, 11, 1107.	2.5	8
26	Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study. Multiple Sclerosis Journal, 2020, 26, 912-923.	3.0	52
27	Using Acute Optic Neuritis Trials to Assess Neuroprotective and Remyelinating Therapies in Multiple Sclerosis. JAMA Neurology, 2020, 77, 234.	9.0	17
28	Rebound of multiple sclerosis activity after fingolimod withdrawal due to planning pregnancy: Analysis of predisposing factors. Multiple Sclerosis and Related Disorders, 2020, 38, 101483.	2.0	23
29	Hashimoto encephalopathy in the 21st century. Neurology, 2020, 94, e217-e224.	1.1	92
30	Characterization of multiple sclerosis lesions with distinct clinical correlates through quantitative diffusion MRI. NeuroImage: Clinical, 2020, 28, 102411.	2.7	11
31	New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab. Frontiers in Neurology, 2020, 11, 579438.	2.4	9
32	Impact of Cognitive Reserve and Structural Connectivity on Cognitive Performance in Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 581700.	2.4	8
33	Retinal and brain damage during multiple sclerosis course: inflammatory activity is a key factor in the first 5 years. Scientific Reports, 2020, 10, 13333.	3.3	20
34	Treatment and outcome of aquaporin-4 antibodyâ€“positive NMOSD. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	37
35	Effects of <scp>IgLON5</scp> Antibodies on Neuronal Cytoskeleton: A Link between Autoimmunity and Neurodegeneration. Annals of Neurology, 2020, 88, 1023-1027.	5.3	61
36	Seizures and epilepsy of autoimmune origin: A long-term prospective study. Seizure: the Journal of the British Epilepsy Association, 2020, 81, 157-165.	2.0	13

#	Article	IF	Citations
37	Clinical significance of Kelch-like protein 11 antibodies. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	54
38	Telemedicine assessment of long-term cognitive and functional status in anti-leucine-rich, glioma-inactivated 1 encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	29
39	GAD antibodies in neurological disorders â€" insights and challenges. Nature Reviews Neurology, 2020, 16, 353-365.	10.1	134
40	Clinical significance of anti-NMDAR concurrent with glial or neuronal surface antibodies. Neurology, 2020, 94, e2302-e2310.	1.1	94
41	CSF levels of glutamine synthetase and GFAP to explore astrocytic damage in seronegative NMOSD. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 605-611.	1.9	17
42	A New Risk Variant for Multiple Sclerosis at 11q23.3 Locus Is Associated with Expansion of CXCR5+ Circulating Regulatory T Cells. Journal of Clinical Medicine, 2020, 9, 625.	2.4	5
43	Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. Lancet Neurology, The, 2020, 19, 234-246.	10.2	207
44	Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. Journal of Neuroinflammation, 2019, 16, 134.	7.2	115
45	Chronic inflammatory demyelinating polyneuropathy associated with contactin-1 antibodies in a child. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, .	6.0	13
46	Late-onset neuromyelitis optica spectrum disorder. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, .	6.0	44
47	Modified connectivity of vulnerable brain nodes in multiple sclerosis, their impact on cognition and their discriminative value. Scientific Reports, 2019, 9, 20172.	3.3	10
48	Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults. Journal of Neurology, 2019, 266, 806-815.	3.6	47
49	Spanish validation of the telephone assessed Expanded Disability Status Scale and Patient Determined Disease Steps in people with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 27, 333-339.	2.0	17
50	Frequency and relevance of IgM, and IgA antibodies against MOG in MOG-IgG-associated disease. Multiple Sclerosis and Related Disorders, 2019, 28, 230-234.	2.0	18
51	Anti-MOG encephalitis mimicking small vessel CNS vasculitis. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e538.	6.0	60
52	Clinical and pathogenic significance of IgG, IgA, and IgM antibodies against the NMDA receptor. Neurology, 2018, 90, e1386-e1394.	1.1	120
53	Clinical profile of patients with paraneoplastic neuromyelitis optica spectrum disorder and aquaporin-4 antibodies. Multiple Sclerosis Journal, 2018, 24, 1753-1759.	3.0	71
54	Assessing Biological and Methodological Aspects of Brain Volume Loss in Multiple Sclerosis. JAMA Neurology, 2018, 75, 1246.	9.0	32

#	Article	IF	Citations
55	Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. Lancet Neurology, The, 2018, 17, 760-772.	10.2	422
56	Combined walking outcome measures identify clinically meaningful response to prolonged-release fampridine. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641878000.	3.5	7
57	Magnetic resonance markers of tissue damage related to connectivity disruption in multiple sclerosis. NeuroImage: Clinical, 2018, 20, 161-168.	2.7	22
58	Predictors of vision impairment in Multiple Sclerosis. PLoS ONE, 2018, 13, e0195856.	2.5	21
59	Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates. Multiple Sclerosis Journal, 2018, 24, 1843-1851.	3.0	77
60	Metabolomic signatures associated with disease severity in multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e321.	6.0	89
61	Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. JAMA Neurology, 2017, 74, 459.	9.0	199
62	Vanishing spinal cord after varicella-zoster virus myelitis. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e364.	6.0	1
63	Impairment of decision-making in multiple sclerosis: A neuroeconomic approach. Multiple Sclerosis Journal, 2017, 23, 1762-1771.	3.0	8
64	Structural networks involved in attention and executive functions in multiple sclerosis. NeuroImage: Clinical, 2017, 13, 288-296.	2.7	87
65	Liver injury and glatiramer acetate, an uncommon association: case report and literature review. Therapeutic Advances in Neurological Disorders, 2017, 10, 367-372.	3.5	9
66	Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination. Journal of Neuroinflammation, 2017, 14, 208.	7.2	105
67	Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1005-1015.	1.9	228
68	Neuromyelitis optica spectrum disorders. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e225.	6.0	134
69	Myelin-reactive antibodies initiate T cell-mediated CNS autoimmune disease by opsonization of endogenous antigen. Acta Neuropathologica, 2016, 132, 43-58.	7.7	75
70	Clinical and Immunologic Investigations in Patients With Stiff-Person Spectrum Disorder. JAMA Neurology, 2016, 73, 714.	9.0	135
71	Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes. Journal of Neurology, 2016, 263, 1349-1360.	3.6	112
72	Cerebellar ataxia and autoantibodies restricted to glutamic acid decarboxylase 67 (GAD67). Journal of Neuroimmunology, 2016, 300, 15-17.	2.3	14

#	Article	IF	Citations
73	Anti-LGI1â€“associated cognitive impairment. Neurology, 2016, 87, 759-765.	1.1	264
74	Usefulness of optical coherence tomography to distinguish optic neuritis associated with AQP4 or MOG in neuromyelitis optica spectrum disorders. Therapeutic Advances in Neurological Disorders, 2016, 9, 436-440.	3.5	43
75	Intravenous Immunoglobulin Therapy in a Patient With Anti-Myelin Oligodendrocyte Glycoprotein-Seropositive Neuromyelitis Optica. Clinical Neuropharmacology, 2016, 39, 332-334.	0.7	3
76	Antibodies in acquired demyelinating disorders in children. Multiple Sclerosis and Demyelinating Disorders, 2016, 1, .	1.1	4
77	Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1257-1259.	1.9	89
78	Baseline clinical status as a predictor of methylprednisolone response in multiple sclerosis relapses. Multiple Sclerosis Journal, 2016, 22, 117-121.	3.0	6
79	Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study. Lancet Neurology, The, 2016, 15, 574-584.	10.2	266
80	A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurology, The, 2016, 15, 391-404.	10.2	2,782
81	Pitfalls in the detection of CV2 (CRMP5) antibodies. Journal of Neuroimmunology, 2016, 290, 80-83.	2.3	27
82	Visual field impairment captures disease burden in multiple sclerosis. Journal of Neurology, 2016, 263, 695-702.	3.6	14
83	Autoantibody-boosted T-cell reactivation in the target organ triggers manifestation of autoimmune CNS disease. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 3323-3328.	7.1	105
84	Enhanced mirror activity in â€˜crossedâ€™ reaction time tasks in multiple sclerosis. Clinical Neurophysiology, 2016, 127, 2001-2009.	1.5	5
85	Pituitary-ovary axis and ovarian reserve in fertile women with multiple sclerosis: A pilot study. Multiple Sclerosis Journal, 2016, 22, 564-568.	3.0	36
86	Antibodies to myelin oligodendrocyte glycoprotein in aquaporin 4 antibody seronegative longitudinally extensive transverse myelitis: Clinical and prognostic implications. Multiple Sclerosis Journal, 2016, 22, 312-319.	3.0	79
87	Knowledge Retrieval from PubMed Abstracts and Electronic Medical Records with the Multiple Sclerosis Ontology. PLoS ONE, 2015, 10, e0116718.	2.5	26
88	Improved Framework for Tractography Reconstruction of the Optic Radiation. PLoS ONE, 2015, 10, e0137064.	2.5	39
89	Autologous hematopoietic stem cell transplantation in multiple sclerosis. Neurology, 2015, 84, 981-988.	1.1	201
90	Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder. JAMA Neurology, 2015, 72, 815.	9.0	59

#	Article	IF	Citations
91	Long latency between GAD-antibody detection and development of limbic encephalitis â€“ a case report. BMC Neurology, 2015, 15, 177.	1.8	14
92	Intense immunosuppression for the treatment of an immune reconstitution inflammatory syndrome-like exacerbation after natalizumab withdrawal: a case report. Journal of Neurology, 2015, 262, 219-221.	3.6	3
93	Encephalitis and AMPA receptor antibodies. Neurology, 2015, 84, 2403-2412.	1.1	311
94	Paraneoplastic Neurological Syndromes and Glutamic Acid Decarboxylase Antibodies. JAMA Neurology, 2015, 72, 874.	9.0	169
95	Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. Brain, 2015, 138, 918-931.	7.6	147
96	Dynamics of retinal injury after acute optic neuritis. Annals of Neurology, 2015, 77, 517-528.	5.3	142
97	Long-term follow-up of immunotherapy-unresponsive recurrent tumefactive demyelination. Journal of the Neurological Sciences, 2015, 352, 127-128.	0.6	6
98	Antibodies to Aquaporin 4, Myelin-Oligodendrocyte Glycoprotein, and the Glycine Receptor Î±1 Subunit in Patients With Isolated Optic Neuritis. JAMA Neurology, 2015, 72, 187.	9.0	119
99	MRI characteristics of neuromyelitis optica spectrum disorder. Neurology, 2015, 84, 1165-1173.	1.1	523
100	Telemedicine for Monitoring MS Activity and Progression. Current Treatment Options in Neurology, 2015, 17, 47.	1.8	15
101	Defective sensorimotor integration in preparation for reaction time tasks in patients with multiple sclerosis. Journal of Neurophysiology, 2015, 113, 1462-1469.	1.8	17
102	Update on biomarkers in neuromyelitis optica. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e134.	6.0	104
103	Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Multiple Sclerosis Journal, 2015, 21, 866-874.	3.0	241
104	Antibodies to Inhibitory Synaptic Proteins in Neurological Syndromes Associated with Glutamic Acid Decarboxylase Autoimmunity. PLoS ONE, 2015, 10, e0121364.	2.5	127
105	Abnormal Control of Orbicularis Oculi Reflex Excitability in Multiple Sclerosis. PLoS ONE, 2014, 9, e103897.	2.5	14
106	Randomized Placebo-Controlled Phase II Trial of Autologous Mesenchymal Stem Cells in Multiple Sclerosis. PLoS ONE, 2014, 9, e113936.	2.5	131
107	The multiple sclerosis visual pathway cohort: understanding neurodegeneration in MS. BMC Research Notes, 2014, 7, 910.	1.4	26
108	Determination of Neuronal Antibodies in Suspected and Definite Creutzfeldt-Jakob Disease. JAMA Neurology, 2014, 71, 74.	9.0	59

#	Article	IF	Citations
109	Clinical and Neuropathological Variability in Clinically Isolated Central Nervous System <scp>W</scp>hipple's Disease. Brain Pathology, 2014, 24, 230-238.	4.1	13
110	Targeting B Cells in Neurological Autoimmune Diseases. Milestones in Drug Therapy, 2014, , 219-246.	0.1	0
111	Cognitive functions in multiple sclerosis: impact of gray matter integrity. Multiple Sclerosis Journal, 2014, 20, 424-432.	3.0	47
112	Cerebellar Ataxia and Glutamic Acid Decarboxylase Antibodies. JAMA Neurology, 2014, 71, 1009.	9.0	154
113	Overlapping demyelinating syndromes and antiâ€"Nâ€methylâ€Dâ€aspartate receptor encephalitis. Annals of Neurology, 2014, 75, 411-428.	5.3	405
114	Transâ€synaptic axonal degeneration in the visual pathway in multiple sclerosis. Annals of Neurology, 2014, 75, 98-107.	5.3	206
115	Colour vision impairment is associated with disease severity in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 1207-1216.	3.0	35
116	Optic Neuritis in the Setting of NMDA Receptor Encephalitis. Journal of Neuro-Ophthalmology, 2014, 34, 316-319.	0.8	6
117	Analysis of prognostic factors associated with longitudinally extensive transverse myelitis. Multiple Sclerosis Journal, 2013, 19, 742-748.	3.0	35
118	Retrograde retinal damage after acute optic tract lesion in MS. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 824-826.	1.9	22
119	Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurology, The, 2013, 12, 157-165.	10.2	2,382
120	Encephalitis and GABA _B receptor antibodies. Neurology, 2013, 81, 1500-1506.	1.1	412
121	Retinal periphlebitis is associated with multiple sclerosis severity. Neurology, 2013, 81, 877-881.	1.1	34
122	Antibody Repertoire in Paraneoplastic Cerebellar Degeneration and Small Cell Lung Cancer. PLoS ONE, 2013, 8, e60438.	2.5	70
123	An Optimized Immunohistochemistry Technique Improves NMO-IgG Detection: Study Comparison with Cell-Based Assays. PLoS ONE, 2013, 8, e79083.	2.5	39
124	Outcome Of Pregnancy After Autologous Hematopoietic Stem Cell Transplantation (AHSCT) For Autoimmune Diseases (AD): A Retrospective Study Of The EBMT Autoimmune Diseases Working Party (ADWP). Blood, 2013, 122, 4640-4640.	1.4	0
125	Replication study of 10 genes showing evidence for association with multiple sclerosis: validation of TMEM39A, IL12B and CLBL genes. Multiple Sclerosis Journal, 2012, 18, 959-965.	3.0	28
126	Value of NMO-IgG determination at the time of presentation as CIS. Neurology, 2012, 78, 1608-1611.	1.1	16

#	Article	IF	Citations
127	White matter abnormalities in primary Sjogren syndrome. QJM - Monthly Journal of the Association of Physicians, 2012, 105, 433-443.	0.5	39
128	Cerebrospinal fluid biomarker supported diagnosis of Creutzfeldtâ€“Jakob disease and rapid dementias: a longitudinal multicentre study over 10 years. Brain, 2012, 135, 3051-3061.	7.6	135
129	Consenso espaÃ±ol sobre la utilizaciÃ³n de natalizumab (TysabriÂ®) - 2011. NeurologÃa, 2012, 27, 432-441.	0.7	7
130	Paraneoplastic cerebellar degeneration associated with thymic germinoma. Journal of the Neurological Sciences, 2012, 320, 153-155.	0.6	5
131	Passive Experimental Autoimmune Encephalomyelitis in C57BL/6 with MOG: Evidence of Involvement of B Cells. PLoS ONE, 2012, 7, e52361.	2.5	12
132	Production and Characterization of crosslinked low-density polyethylene foams using waste of foams with the same composition. Polymer Engineering and Science, 2012, 52, 751-759.	3.1	5
133	Analysis of antibodies to surface epitopes of contactin-2 in multiple sclerosis. Journal of Neuroimmunology, 2012, 244, 103-106.	2.3	21
134	Prevalence and immunological spectrum of temporal lobe epilepsy with glutamic acid decarboxylase antibodies. European Journal of Neurology, 2012, 19, 827-833.	3.3	82
135	Influence of Corpus Callosum Damage on Cognition and Physical Disability in Multiple Sclerosis: A Multimodal Study. PLoS ONE, 2012, 7, e37167.	2.5	68
136	Monoclonal antibody therapy-associated neurological disorders. Nature Reviews Neurology, 2011, 7, 165-172.	10.1	120
137	CADASIL: how to avoid the unavoidable?. BMJ Case Reports, 2011, 2011, bcr0820114727-bcr0820114727.	0.5	5
138	Replication of top markers of a genome-wide association study in multiple sclerosis in Spain. Genes and Immunity, 2011, 12, 110-115.	4.1	36
139	Utility of oligoclonal IgG band detection for MS diagnosis in daily clinical practice. Journal of Immunological Methods, 2011, 371, 170-173.	1.4	25
140	Response to immunotherapy in CLIPPERS syndrome. Journal of Neurology, 2011, 258, 2090-2092.	3.6	40
141	GABA _B receptor antibodies in limbic encephalitis and anti-GADâ€“associated neurologic disorders. Neurology, 2011, 76, 795-800.	1.1	258
142	Antiglycine-receptor encephalomyelitis with rigidity. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1399-1401.	1.9	121
143	Analysis of relapses in anti-NMDAR encephalitis. Neurology, 2011, 77, 996-999.	1.1	214
144	Interferon Î²-1bâ€“neutralizing antibodies 5 years after clinically isolated syndrome. Neurology, 2011, 77, 835-843.	1.1	44

#	Article	IF	Citations
145	Antibodies and neuronal autoimmune disorders of the CNS. Journal of Neurology, 2010, 257, 509-517.	3.6	338
146	Abnormal multifocal cerebral blood flow on Tc-99m HMPAO SPECT in a patient with anti-NMDA-receptor encephalitis. Journal of Neurology, 2010, 257, 1568-1569.	3.6	26
147	Clinical significance of glutamic acid decarboxylase antibodies in patients with epilepsy. Epilepsia, 2010, 51, 760-767.	5.1	126
148	The autoimmune disease-associated KIF5A, CD226 and SH2B3 gene variants confer susceptibility for multiple sclerosis. Genes and Immunity, 2010, 11, 439-445.	4.1	79
149	Delayed onset of a second paraneoplastic neurological syndrome in eight patients. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 937-939.	1.9	31
150	T2 hypointense rims and ring-enhancing lesions in MS. Multiple Sclerosis Journal, 2010, 16, 1317-1325.	3.0	16
151	Neurologic Complications of Hematopoietic Cell Transplantation. Seminars in Neurology, 2010, 30, 287-295.	1.4	40
152	Biological agents: New drugs, old problems. Journal of Allergy and Clinical Immunology, 2010, 126, 394-395.	2.9	18
153	The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. Multiple Sclerosis Journal, 2010, 16, 503-510.	3.0	212
154	Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsingâ€”remitting multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 888-892.	3.0	31
155	Plasma exchange for acute attacks of CNS demyelination. Neurology, 2009, 73, 949-953.	1.1	174
156	Neuromyelitis optica and multiple sclerosis in sisters. Multiple Sclerosis Journal, 2009, 15, 269-271.	3.0	26
157	Cerebellar ataxia associated with neuroendocrine thymic carcinoma and GAD antibodies. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 696-697.	1.9	25
158	Cytotoxic effect of neuromyelitis optica antibody (NMO-IgG) to astrocytes: An in vitro study. Journal of Neuroimmunology, 2009, 215, 31-35.	2.3	91
159	Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurology, The, 2009, 8, 987-997.	10.2	322
160	Cerebrospinal fluid biomarkers in human genetic transmissible spongiform encephalopathies. Journal of Neurology, 2009, 256, 1620-1628.	3.6	77
161	Realce tardÃo del gadolinio en la miocardiopatÃa no compactada. Revista Espanola De Cardiologia, 2009, 62, 822-823.	1.2	4
162	ZIC antibodies in paraneoplastic cerebellar degeneration and small cell lung cancer. Journal of Neuroimmunology, 2008, 201-202, 163-165.	2.3	46

#	Article	IF	Citations
163	Cannabis use in Spanish patients with multiple sclerosis: Fulfilment of patients' expectations?. Journal of the Neurological Sciences, 2008, 273, 103-107.	0.6	20
164	Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain, 2008, 131, 2553-2563.	7.6	536
165	Limbic encephalitis. Neurology, 2008, 70, 500-501.	1.1	36
166	Anti-Hu-associated brainstem encephalitis. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 80, 404-407.	1.9	95
167	Central hypoventilation as the presenting symptom in Hu associated paraneoplastic encephalomyelitis. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 1143-1145.	1.9	16
168	Paraneoplastic limbic encephalitis associated with potassium channel antibodies: value of anti-glial nuclear antibodies in identifying the tumour. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 204-205.	1.9	35
169	Influence of timing on CSF tests value for Creutzfeldt-Jakob disease diagnosis. Journal of Neurology, 2007, 254, 901-906.	3.6	72
170	Revised diagnostic criteria for neuromyelitis optica (NMO). Journal of Neurology, 2007, 254, 1233-1237.	3.6	85
171	Fatal Familial Insomnia. Psychosomatics, 2006, 47, 527-528.	2.5	6
172	Autologous haematopoietic-stem-cell transplantation for multiple sclerosis. Lancet Neurology, The, 2005, 4, 54-63.	10.2	67
173	P/Q-type calcium channel antibodies, Lambertâ€“Eaton myasthenic syndrome and survival in small cell lung cancer. Journal of Neuroimmunology, 2005, 164, 161-165.	2.3	65
174	BR serine/threonine kinase 2: A new autoantigen in paraneoplastic limbic encephalitis. Journal of Neuroimmunology, 2005, 170, 186-190.	2.3	35
175	Acute disseminated encephalomyelitis associated with Campylobacter jejuni infection and antiganglioside GM1 IgG antibodies. Journal of Neurology, 2005, 252, 613-614.	3.6	12
176	Neurological Complications of Hematopoietic Cell Transplantation. Seminars in Neurology, 2004, 24, 427-434.	1.4	35
177	Discrepancies in the Clinical Utility of the 14-3-3 Protein for the Diagnosis of Sporadic Creutzfeldt-Jakob Disease. Archives of Neurology, 2004, 61, 604.	4.5	3
178	Clinical analysis of anti-Ma2-associated encephalitis. Brain, 2004, 127, 1831-1844.	7.6	681
179	Changes of matrix metalloproteinase-9 and its tissue inhibitor (TIMP-1) after autologous hematopoietic stem cell transplantation in multiple sclerosis. Journal of Neuroimmunology, 2004, 153, 190-194.	2.3	16
180	Carbonic anhydrase-related protein VIII: Autoantigen in paraneoplastic cerebellar degeneration. Annals of Neurology, 2004, 56, 575-579.	5.3	60

#	Article	IF	Citations
181	Tau protein in cerebrospinal fluid: a possible marker of poor outcome in patients with early relapsing-remitting multiple sclerosis. Neuroscience Letters, 2004, 363, 14-17.	2.1	41
182	No association of inducible nitric oxide synthase gene (NOS2A) to multiple sclerosis. Journal of Neurology, 2003, 250, 598-600.	3.6	18
183	Voltageâ€gated potassium channel antibodies in limbic encephalitis. Annals of Neurology, 2003, 54, 530-533.	5.3	162
184	CD34+ selected autologous peripheral blood stem cell transplantation for multiple sclerosis: report of toxicity and treatment results at one year of follow-up in 15 patients. Haematologica, 2003, 88, 306-14.	3.5	90
185	14-3-3 protein isoforms and atypical patterns of the 14-3-3 assay in the diagnosis of Creutzfeldtâ€“Jakob disease. Neuroscience Letters, 2002, 320, 69-72.	2.1	30
186	Immunohistochemical analysis of anti-Hu-associated paraneoplastic encephalomyelitis. Acta Neuropathologica, 2002, 103, 509-515.	7.7	154
187	Analysis of the exon 1 polymorphism in the Tau gene in transmissible spongiform encephalopathies. Journal of Neurology, 2002, 249, 938-939.	3.6	13
188	The impact of the introduction of the 14-3-3 protein assay in the surveillance of sporadic Creutzfeldt-Jakob disease in Catalonia. Journal of Neurology, 2001, 248, 592-594.	3.6	14
189	No evidence of CNS infection with Chlamydia pneumoniae in patients with multiple sclerosis. Journal of Neurology, 2001, 248, 617-618.	3.6	19
190	Cerebellar Ataxia With Antiâ€“Glutamic Acid Decarboxylase Antibodies. Archives of Neurology, 2001, 58, 225.	4.5	371
191	Stiff-man syndrome with vacuolar degeneration of anterior horn motor neurons. Journal of Neurology, 1999, 246, 858-860.	3.6	39
192	Detection of 14-3-3 brain protein in the cerebrospinal fluid of patients with paraneoplastic neurological disorders. Annals of Neurology, 1999, 46, 774-777.	5.3	103
193	Stiff-leg syndrome: A focal form of stiff-man syndrome. Annals of Neurology, 1998, 43, 400-403.	5.3	62
194	Upper-limb dystonia secondary to a midbrain hemorrhage. Movement Disorders, 1996, 11, 96-99.	3.9	16